BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of innovative medical and drug delivery devices, announced today that it has won the European Product Line Strategy Leadership award granted by prestigious consulting firm Frost & Sullivan.

This product leadership award recognizes European companies that have demonstrated an outstanding ability to develop innovative products in a given field. Analysts and consultants from Frost & Sullivan chose the award winner after carrying out a study to identify the best strategies in Europe — particularly for enhancing the customer experience.

BIOCORP stood out from other companies on several complementary criteria highlighting its innovations in the development of medical devices for the pharmaceutical industry and consolidating its position as a pioneer in the field of connected devices: Breadth, Scalability, Technology Leverage, Features, Supply Chain Reliability, Price/Performance Value and Brand Equity.
Click here to consult the Best Practice Research: http://bit.ly/1rydpRI

Frost & Sullivan underlines the high potential of various technologies developed by BIOCORP, which has addressed several global healthcare delivery concerns, finding markets enthusiastically waiting for its solutions. BIOCORP has accurately amalgamated novel and emerging technologies to dramatically increase the access to new product developments by combining the latest innovations in digital transformation with advanced therapeutics’ delivery and administration systems. BIOCORP has made the difference by providing a more automated, less-invasive, more personalized, and precise therapeutics administration technology, along with more comfortable and easier-to-use devices for both patients and clinicians1.
“We are honored to receive this award from Frost & Sullivan. It is highlighting the potential of our innovating technology, which represents a genuine competitive asset and enables us to come up with unique and high-value solutions for the pharmaceutical industry, as well as our strong growth potential on a market eager for new solutions. It is a fair acknowledgment of our team members’ hard work”, said Jacques Gardette, BIOCORP’s CEO.